





European Research Studies Journal 
Volume XXIII, Special Issue 2, 2020      
                                                                                         pp. 733-746 
 
Building Stakeholder Relations through Ongoing  
Engagement and Constructive Dialogue: Lessons from Large 
Biopharmaceutical Companies    
Submitted 12/08/2020, 1st revision 19/09/2020, 2nd revision 28/10/2020, accepted 20/11/2020 
  




Purpose: This study elaborates on how biopharmaceutical companies interact with their 
stakeholders. The paper also emphasises the role of a dialogue with stakeholders as an 
essential element of stakeholder engagement. 
Design/Methodology/Approach: The article provides a multi-case study of 27 large 
biopharmaceutical companies that spent over 1 billion EUR on R&D annually in the period 
of 2017-2018. The study employs content analysis of the annual statements, CSR, sustainability 
and integrated reports as well as stakeholder portals run by the examined companies. The 
contents analysis was performed using predefined questions and processed both qualitatively 
and quantitatively. 
Findings: The results of the research indicate that a small number of companies developed 
both stakeholder engagement policies and processes. However, the degree of stakeholder 
involvement in the materiality determination processes should be positively assessed. Nearly 
half of the examined companies explained how they engaged stakeholders in determining 
material issues. 
Practical Implications: The study provides evidence that maintenance of sustainable relations 
with stakeholders by biopharmaceutical companies entails the necessity of a multifaceted 
approach based on the development of engagement policies and processes as well as 
stakeholder engagement activities and methods. 
Originality/Value: The study adopts a multi-stakeholder approach while searching for 
appropriate engagement methods to build a constructive dialogue with stakeholders. 
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The importance of biopharmaceutical companies to the stability and reliability of 
healthcare systems is undeniable, and the COVID-19 pandemic drew the general 
public’s attention to that sector like never before. The development of medicines that 
would help healthcare institutions worldwide gain control over the crisis, and 
vaccines, reducing the risk of the crisis re-emerging in the future became the priority. 
Even in the wealthiest countries with efficient healthcare systems operational burden 
and cost to be incurred were overwhelming (Comite, 2020). With this in mind, any 
investment in R&D activities carried out by the biopharmaceutical sector seems to be 
legitimate. However, there will be, and already are, questions raised whether the 
biopharmaceutical sector is to be the primary beneficiary of the crisis. Therefore, to 
ensure their social license to operate and prosper economically, biopharmaceutical 
companies– similar to the healthcare sector institutions (Pizzi et al., 2020) – must 
conduct a constructive dialogue with stakeholders. 
 
On the one hand, through this dialogue, the companies communicate their actions 
transparently and justify decisions comprehensively. On the other one, the dialogue 
helps them to understand social needs and expectations better and to formulate a 
policy on how to contribute to the improvement of the public health standards 
continuously. Stakeholder diversity makes business activities of biopharmaceutical 
companies converge with the interest of individuals, other enterprises and institutions. 
Therefore, biopharmaceutical companies build and maintain relationships with 
various stakeholders, to obtain knowledge about their specific concerns and priorities. 
Such a multi-stakeholder approach exemplify citizen-centred and sustainable policy 
of an accountable organisation. Thus, socially aware biopharmaceutical companies 
may self-reflect and refine their transparency and disclosure practices regularly, 
taking into account a broad societal context. 
 
The large biopharmaceutical companies that carry out complex R&D projects aiming 
at the creation of breakthrough therapies and products are under continuous 
assessment by multiple interest groups. Those groups should be identified and their 
importance to an organisation determined. It needs to be emphasised that besides the 
value for stakeholders biopharmaceutical companies also produce positive or negative 
externalities of a social or environmental nature. These are marginal benefits or costs 
that go beyond the interest of the companies and may act to the advantage or detriment 
of society (Knauer and Serafeim, 2014). Therefore, stakeholders should be involved 
in the research and business activities of the companies early enough, as to increase 
the likelihood of meeting their expectations concerning social accountability and 
business ethics. Stakeholder inclusiveness may take various forms. Durham et al. 
(2014) specify four levels of the inclusiveness based on informing, consulting, 
engaging and cooperating. The first two represent one-way communication processes 
that aim to “influence stakeholders to agree with a decision that has already been 
made” (Pandi-Perumal et al., 2015). The other two concern bidirectional processes 
that are based on interaction with particular groups to reach the desired outcome and 





improve social accountability and transparency (Deverka et al., 2012; Pandi-Perumal 
et al., 2015). The choice of an adequate form of stakeholder inclusiveness depends on 
management approach and stakeholder importance. 
 
The purpose of this paper is to examine how biopharmaceutical companies build 
interaction networks with their stakeholders through ongoing stakeholder engagement 
and constructive dialogue. Our study provides original empirical evidence on the state 
and character of relationships between biopharmaceutical companies and their 
stakeholders. 
 
2. Research Sample and Method 
 
The research sample in this study is purposive. We collected financial data from the 
ranking of the world-leading 2500 companies regarding their R&D expenditure (IRI, 
2016, 2017, 2018). The sample consists of 27 biopharmaceutical companies whose 
R&D expenditures in the years 2016-2018 surpassed 1 billion EUR3. The majority of 
organisations analysed were involved in global operations and achieved sales 
revenues exceeding 10 billion EUR.  
 
We focused on large biopharmaceutical companies since the development of 
sustainable stakeholder relationships is particularly crucial for them both from social 
accountability reasons and a political perspective. They have to consider the 
heterogeneity of interest between stakeholder groups insightfully. Moreover, to ensure 
the legitimacy and credibility of business activity, they should assure that vast 
amounts spent on R&D projects are allocated in compliance with the public interest 
(Abelson et al., 2003; Deverka et al., 2012; Esmail et al., 2015). 
 
To explore how biopharmaceutical companies maintained sustainable stakeholder 
relationships, we scrutinised corporate annual reports, including CR, CSR, 
sustainability and integrated reports. We also analysed other documents such as 
stakeholder engagement policies or factsheets, sustainability updates, codes of 
conducts, statements of commitment, or position papers on collaborating with 
stakeholders as well as the corporate websites. We pursued a content analysis to find 






3Abbott, AbbVie, Allergan, Amgen, Astellas Pharma, AstraZeneca, Bayer, Biogen, 
Boehringer, Bristol-Myers Squibb, Celgene, Daichii Sankyo, Elly Lilly, Gilead Sciences, 
GlaxoSmithKline, Johnson&Johnson, Merck US, Merck DE, Novartis, Novo Nordisk, 
Otsuka, Pfizer, Roche, Sanofi, Shire, Takeda Pharmaceutical, Teva Pharmaceutical. 
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Table 1. Research questions 
Research questions Answer options 
Did a company develop any stakeholder 
engagement policy or/and conduct a 
formal stakeholder engagement 
process? 
− development of a stakeholder engagement policy; 
− development of a formal stakeholder engagement 
process; 
− development of both stakeholder engagement policy 
and process; 
− no information provided. 
Did a company report on specific 
stakeholder engagement activities 
or/and present general stakeholder 
engagement methods? 
− reporting on specific engagement activities; 
− reporting on general stakeholder engagement 
methods; 
− reporting on both aspects simultaneously; 
− no information provided. 
Did a company list or/and describe 
stakeholder engagement aspects in 
general or across particular 
stakeholders? 
− engagement aspects are listed only; 
− engagement aspects are listed across stakeholder 
groups; 
− engagement aspects are depicted; 
− engagement aspects are depicted concerning one or 
two stakeholder groups; 
− engagement aspects are depicted across multiple 
stakeholder groups; 
− no information provided. 
Did a company report on stakeholder 
engagement in a context of the 
materiality determination process 
(MDP)? 
− stakeholder engagement in the MDP is mentioned; 
− stakeholder engagement in the MDP is explained; 
− stakeholder engagement is included in the materiality 
matrix; 
− no information provided. 








Source: Own elaboration. 
 
Firstly, we analysed whether the biopharmaceutical companies developed stakeholder 
engagement policies or conducted a formal stakeholder engagement process. We 
made insight into the practices or approaches adopted in this regard. Secondly, we 
investigated to what extent the analysed entities reported on specific stakeholder 
engagement activities and methods, and how detailed was the information presented.  
 
We identified various engagement methods used in the communication process with 
stakeholder groups. Thirdly, we explored whether the companies defined stakeholder 
engagement in the MDP since stakeholders’ opinions may facilitate alignment of 
common interests and reinforce the identification of the material content of annual 
reports. Finally, we studied whether the analysed entities appreciated a constructive 











3.1. Stakeholder Engagement Policies, Processes and Methods 
 
Stakeholder engagement can be defined as a bi-directional relationship between the 
biopharmaceutical company and stakeholders that results in “informed decision-
making about the prioritisation, conduct and use of research” (Concannon et al., 
2014). In a general context stakeholder engagement means “the process of 
incorporating the ideas and input” from such interest groups as patients, employees, 
suppliers, policy-makers or local communities (Pandi-Perumal et al., 2015). 
 
In our study, we examined whether biopharmaceutical companies developed 
stakeholder engagement policies or conducted a formal stakeholder engagement 
process which should help them in organising the involvement of interest group 
effectively. Evidence suggests that a small number of companies developed both 
stakeholder engagement policies and processes (see Figure 1). Some organisations 
prepared policies, but they were dedicated to a specific group. 
 
Figure 1. Development of stakeholder engagement policies and processes 
 
Source: Own elaboration. 
 
Novartis, for instance, started to build a patient engagement strategy in 2017. The 
purpose was to embed patient engagement in the company’s operations systematically 
and consistently. Novartis reported that a first step was made with an updated 
document – Commitment to Patients and Caregivers – that outlined how the company 
intended to “help patients and caregivers better understand what they can expect from 
Novartis” (Novartis, 2017, p. 31). The professional practices policy statement was 
another document that supported stakeholder engagement (Novartis, 2018). It applied 
to all the company’s Associates and professional practice-related activities conducted 
by third parties on behalf of Novartis. The company established five principles 
facilitating relationships with stakeholders and securing their interest as well as 
assuring the reputation of Novartis. The company stated that all interactions with 
patients, caregivers, and patient organisations were to be ethical, transparent, non-
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Bayer developed a more structured approach to stakeholder engagement based on 
regular reviews of that process. The company accentuated that dialogue with 
stakeholders could be steered. The whole process was divided into four steps 
including stakeholder mapping (preparation and identification), analysis of strengths 
and weaknesses (characterisation and prioritisation), planning (clustering and strategy 
development) and engagement (interaction, analysis and adjustment) (Bayer, 2018). 
In turn, Abbott focused on establishing local engagement strategies. It delivered 
training on stakeholder engagement at critical affiliates across the globe. The training 
focused on identifying local stakeholders, managing engagement risks, and 
developing constructive dialogue processes. The company expected results of local 
engagement to be disclosed in country-level citizenship reports. Abbott highlighted 
that by applying engagement mechanisms, it wanted to stay “well-informed and up to 
date on the major issues of concern to all stakeholders” (Abbott, 2019). 
 
The next research questions analysed concerned reporting on specific stakeholder 
engagement activities and methods (see Figures 2 and 3). 
 
Figure 2. Content of stakeholder engagement reporting 
 
Source: own elaboration. 
 
Figure 3. Description of stakeholder engagement 
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The evidence shows that the majority of the companies considered in this study 
provided information about specific engagement activities (78%). Moreover, almost 
every second company depicted engagement aspects for several stakeholder groups. 
Only one company revealed nothing about this area. 
 
There are two ways of how organisations interact with their stakeholders. Some prefer 
digital engagements, such as e-communication platforms, social media or mobile-
enabled surveys. The others want to focus on direct communication based on face-to-
face conversations, fora, roundtable discussions or lunch talks. In any case, the process 
of engaging stakeholders should be systematic, continuous and based on internal 
compliance policies on relationships with individuals or interest groups. 
 
Another vital issue is a motivation that leads companies to involve internal and 
external individuals or entities in problems that are material for their business. 
Interaction with stakeholders may be induced by their needs for reliable, factual and 
detailed information that goes beyond corporate reporting. The other reason for 
engagement is the creation of long-term partnerships like, for example, scientific 
collaboration in R&D projects which requires knowledge and intellectual property 
sharing. 
 
Eli Lilly stressed that through partnerships, it could engage stakeholders in public 
policy (Eli Lilly, 2014). Such crucial issues concerned the improvement of patient 
access to treatment options and possible market-oriented solutions in healthcare. 
Moreover, partnerships were conducted to raise awareness about various disease 
states and treatments. 
 
Companies may choose to use one-way communication and provide educational 
information, tools, and resources to a culturally diverse society. Consideration of the 
diversity causes that innovative solutions may serve varied populations, offering high 
medical standards of care to all patients globally. 
 
Through positive and valuable feedback from stakeholders, a biopharmaceutical 
company obtains the desired outcomes, delivers value to particular stakeholder groups 
and impacts societies. In this context, patients, caregivers and healthcare professionals 
may expect that the company will provide innovative medicines, enhance patients’ 
quality of life, improve community-based healthcare and, finally, deliver quality 
medical information. Shareholders and potential investors may thus assume that their 
financial returns will be stable. Business partners should expect fair and free 
competition. Employees will look for comfortable work environments and 
opportunities for developing skills. Finally, society and politicians may expect a 
company to help address, for example, climate change and biodiversity issues (Daiichi 
Sankyo Group, 2018). 
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3.2 Stakeholder Engagement in the Materiality Determination Process 
 
Stakeholder engagement supports the alignment of common interests of both a 
company and its interest groups as well as identification of material content for CSR 
or sustainability reporting (Herremans et al., 2016; Manetti, 2011; Moratis and 
Brandt, 2017). Ray and Miller claim that “stakeholder engagement is an emerging 
field with little evidence to inform best practices” (Ray and Miller, 2017). The 
evidence shows that companies do not involve stakeholders in decision-making 
concerning the content of reports (Manetti, 2011). That decreases the relevance of the 
reported information as well as its credibility and usefulness for stakeholders (Moratis 
and Brandt, 2017). 
 
Our aim was, therefore, to explore and confirm whether biopharmaceutical companies 
reported on stakeholder engagement in the context of the MDP. The evidence showed 
that every third company only mentioned that stakeholders were engaged in the MDP, 
whereas 44% of the examined organisations explained stakeholders’ involvement in 
detail (see Figure 4). 
 
Figure 4. Reporting on stakeholder engagement in a context of the MDP 
 
Source: Own elaboration. 
 
Celgene accentuated that its stakeholder engagement process contributed to the 
improvement of a materiality assessment. The process developed by the company was 
divided into two steps (Celgene, 2018). The first, aimed at analysing social and 
traditional media coverage of the corporate material issues. The second one consisted 
of the adjustment of the relative positioning of critical topics in the materiality matrix. 
To achieve a final concurrence, the materiality matrix was revealed to over 50 external 
stakeholders to obtain feedback. The suggestions were included in the revised 
materiality matrix. Celgene updated the materiality matrix periodically taking into 
account stakeholders’ opinions. That approach helped shape the content of the 
corporate responsibility report. 
 
In other examined biopharmaceutical companies, the MDP was rigorous, robust and 
comprehensive. AstraZeneca, for instance, underlined that it took innovative 
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data tools. The MDP was formal and covered several specific steps (AstraZeneca, 
2018): 
 
− interactive prioritisation workshop with organisation’s Sustainability Advisory 
Board consisting of external sustainability experts and internal leaders; 
− collection of data about external stakeholder priorities on pharmaceutical sector 
megatrends and emerging issues using online and social media tools; 
− interviews with 20 external representatives from key stakeholder groups and 19 
employees across all career levels and locations; 
− assessment of the employees’ views using in-depth surveys (150 survey forms); 
− a focus group for employees (20 persons); 
− crowdsourcing through online quizzes open to all employees; 
− analysing the results concerning corporate business strategy and risk 
management. 
 
Exploration of annual reports of biopharmaceutical companies provides vital 
conclusions. First of all, organisations indicate that by listening to stakeholders, they 
obtain valuable feedback which helps to revise corporate strategy development and 
risk management planning. Stakeholders’ participation in the MDP guarantees that 
concerns relevant to sustainable development will be raised. Organisations may also 
refine their strategies by examining megatrends to determine which social, 
environmental and governance issues matter the most. Finally, stakeholder 
engagement in the MDP may generate measurable benefits. In this respect, we 
checked whether companies that explained how they engaged their stakeholders in the 
MDP recorded positive outcomes in two subsequent years – 2017 and 2018 (see Table 
2). 
 























R&D expenses (t) 12 19,083 15 9,933 29,000 -2,977 0,002 
R&D expenses (t-1) 12 19,417 15 9,667 25,000 -3,170 0,001 
Net sales (t) 12 18,083 15 10,733 41,000 -2,390 0,016 
Net sales (t-1) 12 18,417 15 10,467 37,000 -2,586 0,009 
Operating profits (t) 12 19,250 15 9,800 27,000 -3,075 0,001 
Operating profits (t-1) 12 20,083 15 9,133 17,000 -3,562 0,000 
Profitability ratio (%) (t) 12 18,417 15 10,467 37,000 -2,586 0,009 
Profitability ratio (%) (t-1) 12 18,917 15 10,067 31,000 -2,879 0,003 
Market capitalization (t) 12 18,750 15 8,400 21,000 -3,240 0,001 
Market capitalization (t-1) 12 17,750 15 9,200 33,000 -2,623 0,008 
Source: Own elaboration. 
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The evidence shows significant differences (in most cases with p < 0.01) in terms of 
R&D expenses, net sales, operating profits, profitability ratios and market 
capitalisation between the companies that disclosed how they engaged their 
stakeholders in the MDP and those that did not. The results were validated using the 
non-parametric test. It was proven that the entities that engaged stakeholders in the 
MDP spent more on R&D, recorded higher net sales and operating profits, were more 
profitable and their market values were higher than those of companies who did not 
involve stakeholders in the MDP. 
 
3.3 Role of Stakeholder Engagement and Constructive Dialogue 
 
Some researchers state that by engaging stakeholders, organisations may “anticipate, 
understand, and respond faster and more easily to changes in the rapidly changing 
business environment” (Ayuso et al., 2011). Moreover, bidirectional communication 
should create opportunities for generating innovative ideas that will be beneficial both 
for the company and its stakeholders. Other authors stress that “stakeholder 
engagement in research aims to improve research quality through the incorporation of 
multiple perspectives” (Ray and Miller, 2017). 
 
It should be noted that stakeholder engagement may be mobilised at all levels of the 
company hierarchy, starting with employees at production sites, via senior 
management in business segments and functional departments, to executive 
committees and board of directors. There is a need to develop new collaboration 
models between healthcare professionals and technology providers, as well as other 
stakeholders. Based on the alignment of goals and values companies should decide 
which stakeholder groups they should cooperate with respecting the ability to improve 
human health, enhance social, environmental and stimulate mutual learning (Johnson 
& Johnson, 2017). 
 
The analysis carried out in this study demonstrated that almost every fifth company 
did not report benefits related to stakeholder engagement. The potential advantages 
declared by the rest of the entities can be categorised depending on their relevance to 
stakeholders or the company itself (see Table 3). 
 
Table 3. Key benefits of stakeholder engagement 
Benefits to stakeholders Benefits to biopharmaceutical companies 
− responding to the expectations and needs 
of diverse stakeholders, 
− obtaining reliable and factual 
information about the company’s 
activities, 
− collecting information that is clear and 
helpful to understand R&D projects, 
− building and sustaining trust in long-term 
relationships with a company, 
− forming and maintaining ethical 
relations, 
− identifying global trends and understanding 
challenges, 
− enabling formal and informal consultation 
processes, 
− determining material issues on which a 
company has the most significant impact, 
− receiving stakeholders’ feedback and including 
it in strategy development and risk 
management, 
− building successful strategies and contributing 
to mission achievement. 





− receiving dedicated and more effective 
healthcare solutions, 
− obtaining the best products in the forms 
of innovative and transformative 
medicines and vaccines, 
− benefiting from the value created across 
the whole healthcare system. 
− validating decision-making processes, 
− forging new partnerships and improving the 
development of new medicines, 
− providing the opportunity for expressing 
concerns respecting sustainable and 
responsible business, 
− understanding how different treatments work in 
individual cases due to the involvement of 
patients. 
Source: Own elaboration. 
 
Regular and constructive dialogue is an essential element of stakeholder engagement. 
It helps to understand commercial business, governance and sustainability initiatives 
of the entity as well as enhance its ability to create sustainable value. Bidirectional 
communication enables to comprehend how to serve patients, their caretakers and 
physicians better. Through the dialogue with stakeholders, a company can develop 
performance-based treatment solutions at manageable cost and more adjusted to 
stakeholders’ needs. The two-way communication helps to inform about strategy, 
decisions, actions and performance in a transparent way giving a company social 
license to operate. Moreover, by cultivating a robust dialogue, a company can 
understand different viewpoints and explain its position. Despite these arguments, 
some of the examined entities did not emphasise the importance of stakeholder 




Generating sustainable wealth by organisations depend on abilities to create and 
maintain stable relations with their stakeholder network (Perrini and Tencati, 2006). 
Sustainable stakeholder relationships become a content of “the guiding principle for 
the managerial decision-making process and the pillar of a more comprehensive 
corporate strategy” (Perrini and Tencati, 2006). Moreover, the knowledge that 
stakeholders share with a company and their critical feedback are both seen as a 
reliable support to business operations, and the prerequisite to sustainable 
development (Cavicchi, 2017). Therefore, stakeholder input allows managers to make 
informed decisions, develop sound strategies, shape suitable forms of dialogue with 
internal and external partners and improve or adjust corporate policies and programs. 
 
Our study demonstrates that the maintenance of relations with stakeholders by 
biopharmaceutical companies requires a multifaceted approach and may take different 
forms, from informing and consulting to collaborating. We contribute to the literature 
by identifying several methods of how organisations may interact with their 
stakeholders. The distinction was made between different stakeholder groups and 
various types of engagement with a focus on digital engagements, direct 
communication and indirect communication.  
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The purposeful selection of communication channels as well as methods (Raucci and 
Tarquinio, 2015) to inform on or discuss non-financial issues and performance is still 
insufficiently and unevenly addressed across industries and markets (Tarquinio et al., 
2018). In this respect, our paper emphasises the role of a dialogue with stakeholders 
by which a biopharmaceutical company can develop performance-based treatment 
solutions at manageable cost and adjusted to stakeholders’ needs. We claim that 
conducting an intense dialogue with stakeholders may help a company understand 
different viewpoints and explain its position. 
 
Stakeholder engagement is still perceived as an emerging field of study, mainly due 
to little evidence on best practices (Ray and Miller, 2017). This raises the need to 
verify the present status and propose model solutions that will be tailored to the needs 
of specific industries. That, however, requires the involvement of stakeholders in 
decision-making on the content of annual reports and time for checking whether the 
solutions applied generated effects. In a broader context, maintenance of sustainable 
stakeholder relationships in the biopharmaceutical sector, that comprises a 
considerable number of actors involved in innovative projects, will enhance the 
transparency of research results and magnify research impacts.  
 
The involvement of policy-makers, investigators, product makers, payers and patients 
offers a real promise in developing medicines and therapies contributing to the well-
being of the last key stakeholder group. Therefore, it is expected that future research 
will focus on how to integrate partners in conducting the innovative project and how 
to evaluate stakeholder engagement efforts and outcomes from multiple perspectives 
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